|
1
|
Röllig C, Knop S and Bornhäuser M:
Multiple myeloma. Lancet. 385:2197–2208. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ghobrial IM, Siegel DS, Vij R, Berdeja JG,
Richardson PG, Neuwirth R, Patel CG, Zohren F and Wolf JL: TAK-228
(formerly MLN0128), an investigational oral dual TORC1/2 inhibitor:
A phase I dose escalation study in patients with relapsed or
refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's
macroglobulinemia. Am J Hematol. 91:400–405. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Agarwal A and Mahadevan D: Novel targeted
therapies and combinations for the treatment of multiple myeloma.
Cardiovasc Hematol Disord Drug Targets. 13:2–15. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hao S, Du X, Song Y, Ren M, Yang Q, Wang
A, Wang Q, Zhao H, Du Z and Zhang G: Targeted gene therapy of the
HSV-TK/hIL-12 fusion gene controlled by the hSLPI gene promoter of
human non-small cell lung cancer in vitro. Oncol Lett.
15:6503–6512. 2018.PubMed/NCBI
|
|
6
|
Morris LG and Chan TA: Therapeutic
targeting of tumor suppressor genes. Cancer. 121:1357–1368. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ling H, Fabbri M and Calin GA: MicroRNAs
and other non-coding RNAs as targets for anticancer drug
development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liang S, Zhang N, Deng Y, Chen L, Zhang Y,
Zheng Z, Luo W, Lv Z, Li S and Xu T: miR-663 promotes NPC cell
proliferation by directly targeting CDKN2A. Mol Med Rep.
16:4863–4870. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi J: Regulatory networks between
neurotrophins and miRNAs in brain diseases and cancers. Acta
Pharmacol Sin. 36:149–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petri R and Jakobsson J: Identifying miRNA
targets using AGO-RIPseq. Methods Mol Biol. 1720:131–140. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trionfini P and Benigni A: MicroRNAs as
master regulators of glomerular function in health and disease. J
Am Soc Nephrol. 28:1686–1696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Orso F, Quirico L, Dettori D, Coppo R,
Virga F, Ferreira LC, Paoletti C, Baruffaldi D, Penna E and Taverna
D: Role of miRNAs in tumor and endothelial cell interactions during
tumor progression. Semin Cancer Biol. 60:214–224. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Muys BR, Sousa JF, Plaça JR, de Araújo LF,
Sarshad AA, Anastasakis DG, Wang X, Li XL, de Molfetta GA, Ramão A,
et al: miR-450a acts as a tumor suppressor in ovarian cancer by
regulating energy metabolism. Cancer Res. 79:3294–3305. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang WC, Jang TH, Tung SL, Yen TC, Chan
SH and Wang LH: A novel miR-365-3p/EHF/keratin 16 axis promotes
oral squamous cell carcinoma metastasis, cancer stemness and drug
resistance via enhancing β5-integrin/c-met signaling pathway. J Exp
Clin Cancer Res. 38:892019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miao X, Wang Z, Chen B, Chen Y, Wang X,
Jiang L, Jiang S, Hao K and Zhang W: miR-140-5p suppresses
retinoblastoma cell proliferation, migration, and invasion by
targeting CEMIP and CADM3. Cell Mol Biol (Noisy-le-grand).
64:42–47. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lan H, Chen W, He G and Yang S: miR-140-5p
inhibits ovarian cancer growth partially by repression of PDGFRA.
Biomed Pharmacother. 75:117–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang D, Yang Y, Wu M, Zhao X, Sun Y, Xie
H, Li H, Li Y, Wang K, Zhang J, et al: The moderating effect of
social support on the relationship between physical health and
suicidal thoughts among Chinese rural elderly: A nursing home
sample. Int J Ment Health Nurs. 27:1371–1382. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ferrara N and Adamis AP: Ten years of
anti-vascular endothelial growth factor therapy. Nat Rev Drug
Discov. 15:385–403. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network;
Analysis Working Group; Asan University; BC Cancer Agency; Brigham
and Women's Hospital; Broad Institute; Brown University; Case
Western Reserve University; Dana-Farber Cancer Institute; Duke
University, et al, . Integrated genomic characterization of
oesophageal carcinoma. Nature. 541:169–175. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Botta C, Di Martino MT, Ciliberto D, Cucè
M, Correale P, Rossi M, Tagliaferri P and Tassone P: A gene
expression inflammatory signature specifically predicts multiple
myeloma evolution and patients survival. Blood Cancer J.
6:e5112016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu L, Bi N, Wu L, Ding X, Men Y, Zhou W,
Li L, Zhang W, Shi S, Song Y and Wang L: MicroRNA-29c functions as
a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol
Cancer. 16:502017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu CY, Hsieh TH, Tsai CF, Tsai HP, Chen
HS, Chang Y, Chuang HY, Lee JN, Hsu YL and Tsai EM: miRNA-199a-5p
regulates VEGFA in endometrial mesenchymal stem cells and
contributes to the pathogenesis of endometriosis. J Pathol.
232:330–343. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai
LS, Zhang L and Hu Y: miR-15a and miR-16 affect the angiogenesis of
multiple myeloma by targeting VEGF. Carcinogenesis. 34:426–435.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers
L, Medeiros LJ, Jorgensen JL and Wang SA: Immunophenotypic
heterogeneity of normal plasma cells: Comparison with minimal
residual plasma cell myeloma. J Clin Pathol. 65:823–829. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Horst A, Hunzelmann N, Arce S, Herber M,
Manz RA, Radbruch A, Nischt R, Schmitz J and Assenmacher M:
Detection and characterization of plasma cells in peripheral blood:
Correlation of IgE+ plasma cell frequency with IgE serum titre.
Clin Exp Immunol. 130:370–378. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang B, Yin JJ and Zhan XR: MiR-301a
promotes cell proliferation by directly targeting TIMP2 in multiple
myeloma. Int J Clin Exp Pathol. 8:9168–9174. 2015.PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fakhri B and Vij R: Clonal evolution in
multiple myeloma. Clin Lymphoma Myeloma Leuk. 16 (Suppl):S130–S134.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kiely F, Cran A, Finnerty D and O'Brien T:
Self-reported quality of life and symptom burden in ambulatory
patients with multiple myeloma on disease-modifying treatment. Am J
Hosp Palliat Care. 34:671–676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kuroda J and Chinen Y: Multiple myeloma:
Pathophysiology and progress in management. Rinsho Ketsueki.
58:487–497. 2017.PubMed/NCBI
|
|
32
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shang J, Chen ZZ, Wang ZH, Wei TN, Wu WB
and Chen WM: Association of miRNA-196b-5p and miRNA-99a-5p with
autophagy and apoptosis in multiple myeloma cells. Zhonghua Xue Ye
Xue Za Zhi. 39:766–772. 2018.(In Chinese). PubMed/NCBI
|
|
34
|
Abdi J, Rastgoo N, Li L, Chen W and Chang
H: Role of tumor suppressor p53 and micro-RNA interplay in multiple
myeloma pathogenesis. J Hematol Oncol. 10:1692017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ren Y, Li X, Wang W, He W, Wang J and Wang
Y: Expression of peripheral blood miRNA-720 and miRNA-1246 can be
used as a predictor for outcome in multiple myeloma patients. Clin
Lymphoma Myeloma Leuk. 17:415–423. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rocci A, Hofmeister CC and Pichiorri F:
The potential of miRNAs as biomarkers for multiple myeloma. Expert
Rev Mol Diagn. 14:947–959. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fang Z, Yin S, Sun R, Zhang S, Fu M, Wu Y,
Zhang T, Khaliq J and Li Y: miR-140-5p suppresses the
proliferation, migration and invasion of gastric cancer by
regulating YES1. Mol Cancer. 16:1392017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang HL, Gao YM and Zhao JA: miR-140-5p
inhibits human glioma cell growth and invasion by targeting JAG1.
Mol Med Rep. 16:3634–3640. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Flamini V, Jiang WG and Cui Y: Therapeutic
role of MiR-140-5p for the treatment of non-small cell lung cancer.
Anticancer Res. 37:4319–4327. 2017.PubMed/NCBI
|
|
40
|
Luo W, Liu L, Yang L, Dong Y, Liu T, Wei
X, Liu D, Gu H, Kong J, Yuan Z and Zhao Q: The vitamin D receptor
regulates miR-140-5p and targets the MAPK pathway in bone
development. Metabolism. 85:139–150. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu D, Yang C, Zhang Z, Cong Y and Xiao M:
Knockdown of Linc00515 inhibits multiple myeloma autophagy and
chemoresistance by upregulating miR-140-5p and downregulating
ATG14. Cell Physiol Biochem. 48:2517–2527. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu Y, Qin T, Li J, Wang L, Zhang Q, Jiang
Z and Mao J: MicroRNA-140-5p inhibits invasion and angiogenesis
through targeting VEGF-A in breast cancer. Cancer Gene Ther.
24:386–392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei R, Cao G, Deng Z, Su J and Cai L:
miR-140-5p attenuates chemotherapeutic drug-induced cell death by
regulating autophagy through inositol 1,4,5-trisphosphate kinase 2
(IP3k2) in human osteosarcoma cells. Biosci Rep. 36:e003922016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nie ZY, Liu XJ, Zhan Y, Liu MH, Zhang XY,
Li ZY, Lu YQ, Luo JM and Yang L: miR-140-5p induces cell apoptosis
and decreases Warburg effect in chronic myeloid leukemia by
targeting SIX1. Biosci Rep. 39:BSR201901502019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang Y and Xu J: MiR-140-5p regulates
hypoxia-mediated human pulmonary artery smooth muscle cell
proliferation, apoptosis and differentiation by targeting Dnmt1 and
promoting SOD2 expression. Biochem Biophys Res Commun. 473:342–348.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Barquet LA: Role of VEGF in diseases of
the retina. Arch Soc Esp Oftalmol. 90 (Suppl 1):S3–S5. 2015.(In
Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang P, Xiong J, Zuo L, Liu K and Zhang H:
miR-140-5p regulates cell migration and invasion of non-small cell
lung cancer cells through targeting VEGFA. Mol Med Rep.
18:2866–2872. 2018.PubMed/NCBI
|
|
49
|
Zhang W, Zou C, Pan L, Xu Y, Qi W, Ma G,
Hou Y and Jiang P: MicroRNA-140-5p inhibits the progression of
colorectal cancer by targeting VEGFA. Cell Physiol Biochem.
37:1123–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
